Search
Tegaserod
go.drugbank.com/drugs/DB01079ApprovedWithdrawn[L5918,F4229] Zelnorm (tegaserod) by Sloan Pharma subsequently gained re-approval in April of 2019.[L5918] Nevertheless, tegaserod remains un-approved in certain regions.
Bisegliptin
go.drugbank.com/drugs/DB06127InvestigationalIt is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion
Nalbuphine
go.drugbank.com/drugs/DB00844ApprovedInvestigationalA narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the Un...
Talsupram
go.drugbank.com/drugs/DB09191ExperimentalIt was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to [citalopram].
Ulotaront
go.drugbank.com/drugs/DB15665Investigational[A193506] SEP-363856 was developed by Sunovion pharmaceuticals. … Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5
XEN-D0101
go.drugbank.com/drugs/DB06020ExperimentalXEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.
Hyperforin
go.drugbank.com/drugs/DB01892InvestigationalNutraceuticalHyperforin is a phytochemical generated by the plants of the Hypericum family.
Sea salt
go.drugbank.com/drugs/DB11266ApprovedSea salt is a food ingredient and is often colored by adding charcoal or red clay to sometimes be referred to as “Hawaiian Sea Salt.”
Synonyms: bay saltGuselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalDeveloped by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.